Cash Swells to $140.7M With Runway to 2H 2029 as Dual INDs Target Year-End
NVCT has more than doubled off its 52-week low of $5.55.
Summary
Nuvectis ended Q3 with $140.7 million in cash, up from $31.6 million at year-end 2025, after a $115 million July follow-on and $39.5 million raised through the ATM. Management says that funds operations into the second half of 2029, well past the near-term regulatory milestones. The $30.1 million quarterly net loss is mostly accounting optics: it includes the $20.0 million Haisco license upfront and $1.8 million of NXP900 milestones, leaving roughly $5.8 million of underlying burn, and the quarter's EPS came in at USD -1.02. The real news is timing — FDA discussions on a US PNH path for ciprocopan (NXP100) are underway with an update promised before year-end, and US IND submissions for both NXP100 and NXP200 are expected by year-end. NXP200's ESMO data showed a 40.0% ORR in high-grade glioma and 42.9% in low-grade glioma, with deep responses in most responders. Watch the year-end FDA update and the two IND filings as the next hard checkpoints.
At the time of this announcement, NVCT was trading at $19.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $631.3M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.